The Hematology Podcast Series!

A discussion between Dr. Daniel A. Pollyea and Dr. Stéphanie DésiletsDr. Pollyea and Dr. Désilets discuss key updates from EHA 2025 on acute myeloid leukemia (AML) treatments. They highlight promising results from trials on menin inhibitors like revumenib, ziftomenib, and bleximenib, especially in combinations with standard therapies.

They also review new venetoclax-based combinations and explore the potential of all-oral regimens to improve access for patients in remote areas. Lastly, they emphasize the value of real-world data to guide future AML treatment strategies.

Stéphanie Désilets, MD

Hemato-oncologist
CIUSSS Estrie-CHUS

Assistant professor at the Université de SherbrookeBio: Dr Désilets completed her specialisation in hemato-oncology at the Université de Sherbrooke. She did her fellowship in Lyon, France, at the Centre Leon Berard in autologous stem cell transplant and acute leukemias. She is currently practicing at the University Hospital in Sherbrooke (CHUS) with a focus on acute leukemias, lymphomas and autologous transplant.

A discussion between Dr. Peter Anglin and Dr. Nathalie Johnson (March 2023)

Dr. Anglin and Dr. Johnson review the recently published Canadian guidelines for front-line CLL. They focus on different patient subgroups, including those with high-risk features such as del(17p) and TP53 mutations, complex cytogenic, unmutated IGHV, as well as those with good performance status and favorable genetic profiles. Continuous vs fixed treatment duration is assessed in the context of comorbidities and patient preferences.

Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON

Nathalie A. Johnson, MD, PhD, FRCPC, Associate Professor McGill University, Department of Medicine, Jewish General Hospital, Montreal, QC

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel A. Pollyea and Dr. Brian Leber (November 2022)

Dr. Pollyea and Dr. Leber examine the new hierarchical AML classification algorithm proposed by the ELN expert panel and discuss its impact on the routine practice and design of future clinical trials in AML. They scrutinize diagnostic and prognostic features, from blast counts and genetic abnormalities to cytogenetic characteristics and diagnostic qualifiers. Finally, they provide insight into how various decision-makers in the US and Canada might react when approving treatment eligibility for patients who, due to the new classification, meet eligibility criteria that were not previously met.

The algorithm discussed is available on the podcast hosting site at www.hematologypodcasts.ca

Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine

Brian Leber, MD, BSc, MDCM, FRCPC, Professor of Medicine (Hematology), McMaster University, Attending Physician and Hematologist. Head, Leukemia Group. Co-Director, Cellular Therapy Programme (formerly Stem Cell Transplant Programme) Director, Molecular Hematology Laboratory, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. William G. Wierda (November 2022)

Dr. Anglin and Dr. Wierda discuss sequencing and factors that drive decisions when initiating treatment and when transitioning from one line of therapy to the next. The discussion zooms in on emerging approaches, their benefits over established treatments and their potential role in the CLL treatment algorithm. The relevance of disease characteristics and prognostic risk factors were summarized, as well as patient-related considerations, in the context of treatment duration (continuous vs fixed), duration of response, and treatment-related toxicities.

Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON

William G. Wierda, MD, PhD, Professor and Medical Director, Department of Leukemia, Executive Medical Director, Leukemia, Lymphoma and Stem Cell Transplant, University of Texas, MD Anderson Cancer Centre

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. John F. Seymour (October 2022)

Dr. Anglin and Dr. Seymour discuss the management of CLL patients progressing on novel continuous therapies (BTK inhibitors) as well as after novel time-limited therapies (venetoclax-based regimens). They emphasize the importance of understanding the underlying reason(s) for progression/treatment failure. Dr. Seymour describes his practice of switching from BTK inhibitors to venetoclax-based therapies and vice versa and factors that impact his approaches and choice of subsequent therapy.

Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON

John F. Seymour, AM, FAHMS, MB, BS, PhD, FRACP, Professor of Medicine, University of Melbourne, Director, Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel A. Pollyea and Dr. Florian Kuchenbauer (September 2022)

In the second episode of the 2022 AML series, Dr. Pollyea and Dr. Kuchenbauer review data presented at the EHA 2022 annual meeting. After zooming in on the QuANTUM-First trial with quizartinib and further discussing treatment strategies and opportunities for FLT3 positive AML, such as the triplet combination of quirzatinib, decitabine and venetoclax, they touch upon promising data with magrolimab, a first-in-class anti-CD47 antibody, in combination with azacitidine in AML patients with the TP53 mutation.

Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine

Florian Kuchenbauer, MD, PhD, FRCPC, Member, Leukemia/Bone Marrow Transplant Program of BC, Associate Director, Hematology Research Program, Michael Smith Health Research BC Scholar, Associate Professor, Department of Medicine, University of British of Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Carolyn Owen (July 2022)

Dr. Anglin and Dr. Owen discuss evidence presented at the EHA 2022 and the impact of the presented data on Canadian routine practice and the management of CLL. The main focus is on trials in the first line setting – ELEVATE-TN with acalabrutinib and CLL14 AND CLL13 with venetoclax-based therapies. Dr. Anglin and Dr. Owen also touch on emerging options for relapsed/refractory disease, in particular, non-covalent (reversible) BTK inhibitor pirtobrutinib (LOXO-305).

Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON

Carolyn Owen, MD, MDres(UK), FRCPC, Hematologist, Tom Baker Cancer Centrex, Associate Professor, Division of Hematology & Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary, Local Principal Investigator, Tom Baker Cancer Centre

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Versha Banerji (June 2022)

Versha Banerji, MD, FRCPC, Clinician Scientist and Associate Professor, Faculty of Medicine, Departments of Internal Medicine, Biochemistry & Medical Genetics, Max Rady School of Medicine, Rady Faculty of Health Sciences, University of Manitoba, CLL clinic and research Co-Lead Hematologist, CancerCare Manitoba, Senior Scientist, CancerCare Manitoba Research Institute, Adjunct Professor, Department of Biology, University of Winnipeg

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel A. Pollyea and Dr. Courtney DiNardo, moderated by Dr. Michelle Geddes (May 2022)

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Stephan Stilgenbauer (May 2022)